<DOC>
	<DOCNO>NCT01090609</DOCNO>
	<brief_summary>The objective study evaluate performance safety Chronus® cobalt-chromium coronary stent patient `` de novo '' native coronary artery lesion treat 19-mm-long stent long-term 9 month .</brief_summary>
	<brief_title>Study Evaluate Safety Cronus® - Cobalt Chromium Coronary Stent</brief_title>
	<detailed_description>The use coronary stent optimize result coronary balloon angioplasty two reason : 1. reduce acute complication , acute subacute occlusion , well need urgent myocardial revascularization ; 2. reduce coronary restenosis . STRESS BENESTENT 1 pivotal clinical trials7,9 lay foundation approval confirmation efficacy coronary stent . These study show reduction binary angiographic restenosis rate 42.1 % 31.6 % ( p &lt; 0.05 ) 32 % 22 % ( p=0.02 ) , respectively . The efficacy coronary stent due fact device reduce acute elastic recoil late negative remodel coronary artery capacity maintain vessel adequately open without reduce vessel diameter . Cronus® stent fabricate cobalt-chromium . This alloy currently use cardiovascular stent permanent implant orthopedic ( hip , knee ) , dental maxillofacial surgery . Guidant Medtronic conduct clinical evaluation stent fabricate similar cobalt-chromium alloy demonstrate safety efficacy investigational device . Both stent currently available European market .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Chromium</mesh_term>
	<mesh_term>Cobalt</mesh_term>
	<criteria>1 . Age ≥18 year ≤75 year ; 2 . Symptomatic cardiac ischemic disease and/or document evidence myocardial ischemia ; 3 . Types B1 B2 coronary lesion ( accord ACC/AHA classification modify Ellis ) ; 4 . Target lesion locate native coronary artery ; 5 . Target lesion vessel diameter range 2.5 3.5 mm ( visual estimate ) amenable treatment ( coverage ) 19mmlong stent ; 6 . Target lesion &gt; 50 % diameter stenosis ( visual estimate ) ; 7 . Acceptable candidate myocardial revascularization surgery ( coronary artery bypass graft surgery ) ; 8 . The subject fully inform nature study , willing comply study requirement provide write informed consent approve Ethics Committee respective clinical site . 1 . Female patient childbearing potential ; 2 . Recent Qwave myocardial infarction occur within 48 hour prior index procedure . Recent Qwave nonQwave myocardial infarction still elevate level cardiac marker ; 3 . Documented leave ventricular ejection fraction &lt; 30 % ; 4 . Renal dysfunction ( creatinine &gt; 2.0 mg/dL 177 µmol/L ) ; 5 . Platelet count &lt; 100,000 cells/mm³ &gt; 700,000 cells/mm³ . ; 6 . White blood cell count &lt; 3,000 cells/mm3 ; 7 . Suspected documented hepatic disease ( include laboratorial evidence hepatitis ) ; 8 . Heart transplant receptor ; 9 . Known hypersensitivity cobaltchromium medication aspirin , clopidogrel bisulfate ( Plavix ISCOVER ) , ticlopidine ( Ticlid ) heparin . 10 . Concurrent medical condition life expectancy le 12 month ; 11 . Any major medical condition , Investigator 's opinion , may interfere optimal participation patient study ; 12 . Subject currently participate investigational drug another device study , include plan participation investigational drug another device study course present investigation ; 13 . Coronary angioplasty ( without stenting ) less 9 month index procedure site target vessel ; 14 . Previous coronary angioplasty ( without stenting ) time ( &gt; 9 month ) vessel segment le 5 mm proximal distal target lesion . 15 . Planned coronary angioplasty ( without stenting ) first 12 month index procedure segment target vessel ; Angiography 1 . Restenotic target lesion ; 2 . More one lesion require treatment vessel ; 3 . Target vessel diameter &lt; 2.5 mm &gt; 3.5 mm ( visual estimation ) ; 4 . Long target lesion amenable treatment ( coverage ) 19mmlong stent ; 5 . Unprotected coronary artery branch lesion ( ≥50 % diameter stenosis ) 6 . Target lesion locate surgical bypass graft ; 7 . Total vessel occlusion ( TIMI flow grade 01 ) ; 8 . Target lesion ostial location ; 9 . Target lesion locate lateral branch bifurcation &gt; 2.5mm require lateral branch stenting ; 10 . Calcified target lesion anticipate unsuccessful/impracticable predilation ; 11 . Target vessel excessive tortuosity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Coronary Stent</keyword>
	<keyword>Cobalt-Chromium coronary stent</keyword>
</DOC>